Eurofins-Cerep SA is a leading company in the field of drug discovery services. Their core values include excellence, innovation, and customer focus. Eurofins-Cerep SA aims to provide high-quality research solutions to pharmaceutical and biotech industries, helping them accelerate the drug discovery process. With a commitment to scientific expertise and market leadership, Eurofins-Cerep SA constantly strives to deliver reliable and timely results. Their corporate philosophy revolves around collaboration, integrity, and continuous improvement, ensuring a strong foundation for their clients' success. By integrating cutting-edge technologies and a customer-centric approach, Eurofins-Cerep SA remains a trusted partner for companies seeking efficient and effective drug discovery solutions.

Eurofins-Cerep SA is primarily present in France, where its headquarters is located. As a leading global provider of discovery services, Eurofins-Cerep SA also has a significant presence in other countries and regions including the United States, India, China, Germany, and the United Kingdom. With its expansive global network, Eurofins-Cerep SA is able to cater to the research and development needs of clients worldwide, offering innovative solutions in drug discovery and development.

Eurofins-Cerep SA, a leading drug discovery services company, has achieved several significant milestones. Over the years, the company has established a strong reputation in the pharmaceutical industry. Eurofins-Cerep SA has successfully provided high-quality drug discovery solutions, including in vitro and in vivo assays, ADME-Tox profiling, and medicinal chemistry optimization. Additionally, they have developed innovative technologies, such as their patented ChemPrint(R) platform, which enables efficient screening of large compound libraries. The company has also forged strategic partnerships with key players in the pharmaceutical and biotech sectors, further enhancing its capabilities and global reach. Eurofins-Cerep SA's commitment to excellence and continuous innovation has solidified its position as a trusted and respected name in the industry.

Eurofins-Cerep SA is a leading company in the field of in vitro screening for drug discovery. Established in 1991, Eurofins-Cerep has built a strong reputation for its expertise in high-throughput screening and pharmacology services. The company offers a comprehensive range of solutions to pharmaceutical and biotechnology industries, helping them to identify potential drug candidates and optimize the development process. Eurofins-Cerep's extensive databases and advanced technologies enable efficient compound profiling and target validation, contributing to the progress of drug research and development. With its rich history and continuous dedication to innovation, Eurofins-Cerep is a trusted partner in the pharmaceutical industry.

The main competitors of Eurofins-Cerep SA in the market are companies like Charles River Laboratories International Inc., WuXi AppTec Co Ltd, Covance Inc., and Evotec SE. These companies also operate in the contract research organization (CRO) industry, offering similar services in drug discovery and development. With its strong position in the market, Eurofins-Cerep SA faces competition from these reputable players.

Eurofins-Cerep SA is primarily active in the pharmaceutical and biotechnology industries.

The business model of Eurofins-Cerep SA is focused on providing drug discovery and development services to the pharmaceutical and biotechnology industry. Eurofins-Cerep offers a wide range of services such as target validation, screening, and lead optimization, enabling clients to make informed decisions in the development of new drugs. With its expertise in high-throughput screening, Eurofins-Cerep helps pharmaceutical companies identify and optimize potential drug candidates efficiently. By combining bioanalytical methods with computational modeling, Eurofins-Cerep contributes to the acceleration of drug discovery processes. Eurofins-Cerep strives to be a trusted partner in drug research, offering innovative solutions to meet the evolving needs of the industry.

De K/W-verhouding kan momenteel niet worden berekend voor Eurofins-Cerep.

De KUV kan momenteel niet worden berekend voor Eurofins-Cerep.

De AlleAktien Kwaliteitsscore voor Eurofins-Cerep is 7/10.

De omzet kan momenteel niet worden berekend voor Eurofins-Cerep.

De winst kan momenteel niet berekend worden voor Eurofins-Cerep.

Eurofins-Cerep SA is a leading provider of biological screening services and offers a wide range of in vitro testing systems and biological assays. The company works closely with customers in the pharmaceutical, biotechnology, and agrochemical industries to assist them in identifying and validating target molecules. Eurofins-Cerep SA covers various areas including drug development, toxicology, functional genomics, and drug safety. Each of these divisions includes specific test systems and services tailored to the needs of customers. In the drug development sector, the company offers high-throughput screenings, in vitro assays, cloning services, cell line studies, receptor expression analysis, and many other services. The toxicology division provides a comprehensive portfolio of in vitro and in vivo tests, as well as angiogenic and biomarker studies. The drug safety group offers a broad range of pharmacological and toxicological studies monitoring the safety of drugs during clinical development and market launch. Another important area of Eurofins-Cerep SA is the functional genomics division, which specializes in genome-wide assays and gene expression analysis. Genomics technology is a critical component of modern drug development, and Eurofins-Cerep SA offers its customers leading technologies and services in this field. The company also collaborates with customers in the agrochemical industry, offering them a wide range of services including metabolomics studies, in vitro and in vivo screenings, toxicity testing, and residue analysis. The portfolio of Eurofins-Cerep SA includes a range of products including assay kits, antibodies, cell lines, plasmids, and other reagents that allow customers to conduct their own in vitro tests. These products are a valuable addition to the company's services, expanding the offerings even further. Overall, Eurofins-Cerep SA is a leading company in the biological screening industry, offering its customers a wide range of services and products tailored to their specific needs. The company works closely with customers to help them identify target molecules and develop new drugs and agrochemicals, playing a crucial role in the healthcare and agricultural industries.

Eurofins-Cerep keert een dividend van 0 EUR uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Eurofins-Cerep of het bedrijf keert geen dividend uit.

De ISIN van Eurofins-Cerep is FR0013256518.

Het WKN van Eurofins-Cerep is A2DT0B.

De ticker van Eurofins-Cerep is ALECR.PA.

Binnen de laatste 12 maanden betaalde Eurofins-Cerep een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Eurofins-Cerep naar verwachting een dividend van 0 EUR betalen.

De dividendrendement van Eurofins-Cerep is momenteel .

Eurofins-Cerep betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Eurofins-Cerep betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 EUR verwacht. Dit komt overeen met een dividendrendement van 0 %.

Eurofins-Cerep wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Eurofins-Cerep van 14-11-2024 ter hoogte van 0 EUR te ontvangen, moest je het aandeel voor de ex-datum op 14-11-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 14-11-2024.

In het jaar 2023 heeft Eurofins-Cerep 0 EUR aan dividenden uitgekeerd.

De dividenden van Eurofins-Cerep worden in EUR uitgekeerd.